ASX:CYP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Cynata Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CYP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CYP's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

1.3%

CYP

-4.0%

AU Biotechs

-1.1%

AU Market


1 Year Return

-29.9%

CYP

7.9%

AU Biotechs

1.7%

AU Market

Return vs Industry: CYP underperformed the Australian Biotechs industry which returned 7.9% over the past year.

Return vs Market: CYP underperformed the Australian Market which returned 1.7% over the past year.


Shareholder returns

CYPIndustryMarket
7 Day1.3%-4.0%-1.1%
30 Day4.5%4.8%10.8%
90 Day-6.9%2.1%8.1%
1 Year-29.9%-29.9%8.9%7.9%5.2%1.7%
3 Year30.6%30.6%118.4%111.3%24.1%8.7%
5 Year118.9%118.9%212.4%193.6%58.8%26.5%

Long-Term Price Volatility Vs. Market

How volatile is Cynata Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cynata Therapeutics undervalued compared to its fair value and its price relative to the market?

5.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CYP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CYP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CYP is unprofitable, so we can't compare its PE Ratio to the XX Biotechs industry average.

PE vs Market: CYP is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYP is good value based on its PB Ratio (5.7x) compared to the AU Biotechs industry average (6.2x).


Next Steps

Future Growth

How is Cynata Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

13.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CYP's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if CYP's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CYP's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if CYP's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CYP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cynata Therapeutics performed over the past 5 years?

-11.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYP is currently unprofitable.

Growing Profit Margin: CYP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYP is unprofitable, and losses have increased over the past 5 years at a rate of 11% per year.

Accelerating Growth: Unable to compare CYP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (9%).


Return on Equity

High ROE: CYP has a negative Return on Equity (-21.67%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cynata Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CYP's short term assets (A$13.9M) exceed its short term liabilities (A$689.7K).

Long Term Liabilities: CYP has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CYP is debt free.

Reducing Debt: CYP has no debt compared to 5 years ago when its debt to equity ratio was 0.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYP has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CYP has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 14.9% each year


Next Steps

Dividend

What is Cynata Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CYP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CYP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average board tenure


CEO

Ross MacDonald (62 yo)

no data

Tenure

AU$454,166

Compensation

Dr. Ross Alexander MacDonald, Ph.D., Grad Dip in Bus Admin serves as the Chief Executive Officer and Managing Director at Cynata Therapeutics Limited (formerly Eco Quest Limited). Dr. MacDonald served as t...


CEO Compensation Analysis

Compensation vs Market: Ross's total compensation ($USD335.28K) is about average for companies of similar size in the Australian market ($USD281.14K).

Compensation vs Earnings: Ross's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Ross MacDonald
MD, CEO & Executive Directorno dataAU$454.17k1.77%
A$ 1.6m
Geoffrey Edward Brooke
Independent Non-Executive Chairman0.33yrAU$107.88k0.066%
A$ 57.7k
Paul Wotton
Independent Non-Executive Director4.5yrsAU$110.00k0.15%
A$ 131.8k
Stewart Washer
Non-Executive Director7.33yrsAU$55.00k1.9%
A$ 1.7m
Igor Slukvin
Member of Scientific Advisory Boardno datano datano data
Darryl Maher
Independent Non-Executive Director0.50yrAU$2.29kno data

4.5yrs

Average Tenure

61yo

Average Age

Experienced Board: CYP's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.7%.


Top Shareholders

Company Information

Cynata Therapeutics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cynata Therapeutics Limited
  • Ticker: CYP
  • Exchange: ASX
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$87.843m
  • Shares outstanding: 117.12m
  • Website: https://www.cynata.com

Location

  • Cynata Therapeutics Limited
  • 62 Lygon Street
  • Level 3
  • Carlton
  • Victoria
  • 3053
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYPASX (Australian Securities Exchange)YesOrdinary SharesAUAUDDec 2007
CYPCHIA (Chi-X Australia)YesOrdinary SharesAUAUDDec 2007
CYYN.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2007
51SDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2007

Biography

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The c...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/03 07:00
End of Day Share Price2020/12/03 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.